Completed Equality Screenings - Quarter 4 - January 2013 - March 2013
Date published:
In fulfilling the commitments within its Equality Scheme the Department equality screens policies to assess the impact and determine if a full Equality Impact Assessment (EQIA) is required.
Documents
- NICE CG 152 - Crohn's disease: management in adults, children and young people
- NICE CG 153 - Psoriasis: the assessment and management of psoriasis
- NICE CG 154 Ectopic pregnancy and miscarriage
- NICE TA 265 - Denosumab for the treatment of bone metastases from solid tumours
- NICE TA 266 - Mannitol dry powder for inhalation for the treatment of cystic fibrosis
- NICE TA 267 - Ivabradine for the treatment of chronic heart failure
- NICE TA 268 - Ipilimumab for previously treated advanced (unresectable or metastatic) malignant melanoma - New FAD with PAS published
- NICE TA 269 - Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive melanoma
- NICE TA 271 - Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy
- NICE TA 272 - Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract